The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-3-((6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2,2-dimethyl-3-oxoindolin-1-yl)methyl)picolinonitrile ID: ALA4787790
Chembl Id: CHEMBL4787790
PubChem CID: 155294462
Max Phase: Preclinical
Molecular Formula: C28H29N7O3
Molecular Weight: 511.59
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: C[C@@H]1CN(c2ncc(-c3ccc4c(c3)N(Cc3cccnc3C#N)C(C)(C)C4=O)cn2)CCN1C(=O)CO
Standard InChI: InChI=1S/C28H29N7O3/c1-18-15-33(9-10-34(18)25(37)17-36)27-31-13-21(14-32-27)19-6-7-22-24(11-19)35(28(2,3)26(22)38)16-20-5-4-8-30-23(20)12-29/h4-8,11,13-14,18,36H,9-10,15-17H2,1-3H3/t18-/m1/s1
Standard InChI Key: BTHCNWXORDNTOR-GOSISDBHSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 511.59Molecular Weight (Monoisotopic): 511.2332AlogP: 2.42#Rotatable Bonds: 5Polar Surface Area: 126.55Molecular Species: NEUTRALHBA: 9HBD: 1#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 13.63CX Basic pKa: 2.72CX LogP: 2.27CX LogD: 2.27Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.55Np Likeness Score: -0.94
References 1. Dietrich JD,Longenecker KL,Wilson NS,Goess C,Panchal SC,Swann SL,Petros AM,Hobson AD,Ihle D,Song D,Richardson P,Comess KM,Cox PB,Dombrowski A,Sarris K,Donnelly-Roberts DL,Duignan DB,Gomtsyan A,Jung P,Krueger AC,Mathieu S,McClure A,Stoll VS,Wetter J,Mankovich JA,Hajduk PJ,Vasudevan A,Stoffel RH,Sun C. (2021) Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design., 64 (1.0): [PMID:33378180 ] [10.1021/acs.jmedchem.0c01280 ]